Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.51 |
| ▸ | GRM5 | P41594 | 1/20 | 0.50 |
| ▸ | ATR | Q13535 | 1/20 | 0.48 |
| ▸ | LCK | P06239 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 5/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.45 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29510654 | 1.00 | ALDH1A1 (0.51) | ALDH1A1GRM5ATRLCKGAA | |
| SCHEMBL29394473 | 0.90 | LCK (0.47) | LCKGAASMN1; SMN2MEN1KMT2A | |
| SCHEMBL27874209 | 0.84 | ALDH1A1 (0.65) | ALDH1A1GAASMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL28997343 | 0.84 | SORT1 (0.48) | GRM5LCKMEN1KMT2ASORT1 | |
| SCHEMBL14622117 | 0.84 | LCK (0.43) | LCKGAASMN1; SMN2MEN1KMT2A | |
| SCHEMBL533505 | 0.84 | RAB9A (0.62) | GRM5SMN1; SMN2MEN1KMT2AMAPT | |
| SCHEMBL22523913 | 0.84 | LCK (0.43) | ATRLCKGAAMEN1KMT2A | |
| SCHEMBL31151002 | 0.84 | RAB9A (0.62) | GRM5SMN1; SMN2MEN1KMT2AMAPT | |
| SCHEMBL1857045 | 0.83 | ALDH1A1 (0.48) | ALDH1A1GRM5ATRLCKGAA | |
| SCHEMBL31009974 | 0.83 | LCK (0.42) | ATRLCKGAAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 158 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4746964-A1 | NEW PYRAZOLOPYRIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2026-05-27 | — | — | EP | disclosed |
| EP-4714499-A2 | POLYAMIDE COMPOUNDS, METHOD FOR PREPARING SAME, AND MEDICAL USE THEREOF | Jiangsu NHWA Pharmaceutical Co., Ltd (CN) | 2026-03-25 | — | — | EP | disclosed |
| WO-2026046976-A1 | PYRAZOLOPYRIDINE PHOSPHATE ESTERS FOR MODULATING SALT-INDUCIBLE KINASE (SIK) | F. HOFFMANN-LA ROCHE AG (CH) | 2026-03-05 | — | — | WO | disclosed |
| EP-4650353-A1 | 4-ALKOXY BENZIMIDAZOLE-6-CARBOXYLIC ACID DERIVATIVE SERVING AS GLP-1 RECEPTOR AGONIST | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2025-11-19 | — | — | EP | disclosed |
| US-20250230129-A1 | POLYAMIDE COMPOUNDS, METHOD FOR PREPARING SAME, AND MEDICAL USE THEREOF | JIANGSU NHWA PHARMACEUTICAL CO., LTD (CN) | 2025-07-17 | — | — | US | disclosed |
| EP-4497754-A1 | POLYAMIDE COMPOUNDS, METHOD FOR PREPARING SAME, AND MEDICAL USE THEREOF | Jiangsu NHWA Pharmaceutical Co., Ltd (CN) | 2025-01-29 | — | — | EP | disclosed |
| WO-2025017078-A1 | NEW PYRAZOLOPYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2025-01-23 | — | — | WO | disclosed |
| WO-2024149080-A1 | 4-ALKOXY BENZIMIDAZOLE-6-CARBOXYLIC ACID DERIVATIVE SERVING AS GLP-1 RECEPTOR AGONIST | 中国科学院上海药物研究所 | 2024-07-18 | — | — | WO | disclosed |
| CN-118344349-A | 4-Alkoxybenzimidazole-6-carboxylic acid derivatives as GLP-1 receptor agonists | 中国科学院上海药物研究所 | 2024-07-16 | — | — | CN | disclosed |
| EP-4126855-B1 | COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTIONS | HOFFMANN LA ROCHE (CH) | 2024-04-24 | — | — | EP | disclosed |
| US-20080004261-A1 | CGRP receptor antagonists | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-03 | — | — | US | disclosed |
| WO-2007146349-A2 | CGRP RECEPTOR ANTAGONISTS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-12-21 | — | — | WO | disclosed |
| CN-101090902-A | Cgrp receptor antagonists | MERCK & CO INC (US) | 2007-12-19 | — | — | CN | disclosed |
| CN-101072771-A | Cgrp receptor antagonists | MERCK & CO INC (US) | 2007-11-14 | — | — | CN | disclosed |
| US-7288655-B2 | α v integrin receptor antagonists | MERCK & CO., INC. (US) | 2007-10-30 | — | — | US | disclosed |
| US-7288655-B2 | α v integrin receptor antagonists | MERCK & CO., INC. (US) | 2007-10-30 | — | — | US | disclosed |
| US-5576320-A | 1-heteruarylazetidines and -pyrrolidines, process for their preparation and pharmaceutical compositions containing them | SANOFI (FR) | 1996-11-19 | — | — | US | disclosed |
| US-5565474-A | 1-heteroarylazetidines and -pyrrolidines process for their preparation and pharmaceutical compositions containing them | SANOFI (FR) | 1996-10-15 | — | — | US | disclosed |
| US-5410057-A | 1-heteroarylazetidines and -pyrrolidines | SANOFI (FR) | 1995-04-25 | — | — | US | disclosed |
| EP-0591030-A2 | 1-Heteroaryl-azetidines and -pyrrolidines as 5-HT3 agonists | SANOFI (FR) | 1994-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250230129-A1 | POLYAMIDE COMPOUNDS, METHOD FOR PREPARING SAME, AND MEDICAL USE THEREOF | ADCYAP1R1, PAICS, AGPS | ALDH1A1 2580/4885GRM5 1961/4885ATR 4162/4885 |
| US-20080004261-A1 | CGRP receptor antagonists | CALCRL, CALCR, GRPR | ALDH1A1 1645/4885GRM5 317/4885ATR 4278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.